Expected breakthrough year against H.I.V. fades as U.S. pulls support, NYT says

Following decades of research and investment to produce new approaches to vaccines that were going into their first significant trials, this was supposed to be a breakthrough year in the struggle against H.I.V., Stephanie Nolen of The New York Times reports. However, these plans were derailed by the Trump administration’s slashing of foreign assistance. There is more potential than before to end the H.I.V. epidemic, but now programs across Africa are struggling to procure drugs the U.S. once supplied, replace lost nurses and lab techs, and restart shuttered programs, scientists and health experts say. ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Pfizer (PFE) and Shionogi (SGIOY) as shareholders, as well as Gilead Sciences (GILD) are makers of HIV prevention treatments.